HEAD AND NECK SQUAMOUS CELL CARCINOMA

This early-stage study tests a new cancer treatment called FT836, which uses donor immune cells specially designed to attack tumors. It is for people with advanced lung, colorectal, breast, ovarian, endometrial, or head and neck cancers that have not responded to standard treatme…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control

Last updated May 01, 2026 15:28 UTC

New trial aims to refine treatment for advanced head and neck cancer

This study compares radiation therapy alone to radiation plus the chemotherapy drug cisplatin in patients with stage III-IVA head and neck cancer who have had surgery. The goal is to see which approach better prevents the cancer from returning. About 189 participants will be enro…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control

Last updated May 01, 2026 15:28 UTC

Engineered immune cells take aim at Hard-to-Treat cancers

This early-phase study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific genetic mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 uses the patient's own immune cells, which ar…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control

Last updated May 01, 2026 15:28 UTC

New drug combo targets Hard-to-Treat cancers in early trial

This study tests an experimental drug called VMD-928, taken as a pill, alone or with pembrolizumab (an immunotherapy) in adults with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug shrinks t…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: VM Oncology, LLC • Aim: Disease control

Last updated May 01, 2026 15:27 UTC

Second radiation plus two new drugs may fight recurrent head and neck cancer

This study is for people whose head and neck cancer has returned after previous treatment. It tests a combination of a second round of radiation, chemotherapy, and two newer drugs (tislelizumab and pamiparib) to see if it is safe and what dose works best. About 30 participants wi…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control

Last updated May 01, 2026 15:27 UTC

Blood test may spare HPV throat cancer patients from unnecessary radiation

This study is for people with HPV-related throat cancer. It tests whether a blood test (ctDNA) can identify patients who are at very low risk of their cancer returning after surgery. If the test is negative, they may not need radiation, which has serious side effects. The goal is…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control

Last updated May 01, 2026 15:26 UTC

New drug targets Hard-to-Treat cancers in early trial

This study tests a new drug, LY4052031, in people with advanced or spreading solid tumors, including bladder, breast, and lung cancers. The drug is designed to attach to a protein on cancer cells and deliver a toxic payload to kill them. The trial has two parts: first to find the…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control

Last updated May 01, 2026 15:26 UTC

New drug combo could shrink head and neck tumors before surgery

This study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink tumors more than the immunotherapy alone in people with stage III-IV head and neck cancer. About 44 participants will receive either the combination …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 01, 2026 15:26 UTC

Experimental virus therapy targets Hard-to-Treat cancers in first human trial

This early-phase study tests a new treatment called VET3-TGI, a virus designed to attack cancer cells and boost the immune system. It is for adults with advanced solid tumors that have not responded to standard therapies. The study aims to find a safe dose when given alone or com…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: KaliVir Immunotherapeutics • Aim: Disease control

Last updated May 01, 2026 15:25 UTC

New drug combo aims to boost immune response in hard-to-treat cancers

This study tests whether adding an experimental drug (GB1211) to the standard immunotherapy pembrolizumab can shrink tumors better than pembrolizumab alone. It includes about 92 adults with advanced melanoma or head and neck cancer that has spread or cannot be removed. Participan…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Providence Health & Services • Aim: Disease control

Last updated Apr 30, 2026 15:52 UTC

New antibody drug CHS-114 enters first human trials for Hard-to-Treat cancers

This early-stage study tests a new drug called CHS-114 in people with advanced solid tumors, including head and neck cancer. The drug is designed to help the immune system fight cancer. The main goals are to check safety and find the right dose, either alone or with another drug …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control

Last updated Apr 30, 2026 15:52 UTC

New drug EPI-326 takes on tough cancers in first human trial

This early-phase study tests a new drug called EPI-326 in people with advanced lung cancer (with a specific EGFR mutation) or head/neck cancer. The main goals are to check safety and find the best dose. About 110 participants will receive the drug to see if it can shrink tumors a…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control

Last updated Apr 30, 2026 15:52 UTC

New drug CTX-8371 enters first human tests for multiple advanced cancers

This early-stage study tests the safety of a new drug called CTX-8371 in people with advanced cancers (lung, breast, lymphoma, head & neck, or melanoma) that have not responded to standard treatments. About 85 participants will receive increasing doses of the drug to find the saf…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Compass Therapeutics • Aim: Disease control

Last updated Apr 30, 2026 15:51 UTC

New combo therapy targets hard-to-treat head and neck cancer

This study tests a new drug called SIBP-03 combined with cetuximab in people with advanced head and neck cancer that has returned or spread. The goal is to see if the combination can shrink tumors or slow the disease. About 81 adults aged 18-75 who have already tried immunotherap…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Shanghai Institute Of Biological Products • Aim: Disease control

Last updated Apr 30, 2026 15:51 UTC

New DNA vaccine combo aims to fight hard-to-treat head and neck cancer

This study tests a combination of a DNA vaccine (GX-188E), an immune booster (GX-I7), and an immunotherapy drug (nivolumab) in people with advanced head and neck cancer linked to HPV types 16 or 18. The goal is to see if this treatment can shrink tumors or slow the disease. About…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control

Last updated Apr 30, 2026 15:50 UTC

New drug SIM0610 enters first human tests for advanced cancers

This early-stage study is testing a new drug, SIM0610, for the first time in people. It aims to see if the drug is safe and tolerable for adults with advanced solid tumors, including lung, colorectal, head and neck, and liver cancers. The study will also look for early signs that…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Apr 30, 2026 15:50 UTC

New drug targets 'Undruggable' cancer mutation in early trial

This early-phase study tests a new drug, CLSP-1025, designed to attack cancer cells that have a specific change in the p53 gene (called R175H). The trial enrolls adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have this mutation and have not respon…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Clasp Therapeutics, Inc. • Aim: Disease control

Last updated Apr 30, 2026 15:50 UTC

New hope for advanced cancers? early trial of DR-0202 begins

This early-phase study tests a new drug called DR-0202 in about 96 people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. Participan…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Dren Bio • Aim: Disease control

Last updated Apr 30, 2026 15:49 UTC

Promising new combo aims to shrink head and neck tumors

This study tests a new combination of drugs (SI-B001 and SI-B003) plus standard chemotherapy as a first treatment for people whose head and neck cancer has come back or spread to other parts of the body. The goal is to see if this combination can shrink tumors or slow the cancer'…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Apr 30, 2026 15:48 UTC

New hope for head and neck cancer: drug works after immunotherapy fails

This study tests whether the drug cetuximab can shrink tumors in people with head and neck cancer that has spread or come back, after they have already tried immunotherapy. About 38 adults will receive cetuximab alone. The main goal is to see how many patients' tumors shrink or d…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control

Last updated Apr 30, 2026 15:48 UTC

New pill shows promise for Hard-to-Treat cancers

This study tests an experimental oral drug called IPN01194 in 220 adults with advanced solid tumours (melanoma, colorectal, pancreatic, or head and neck cancers) that have spread and no longer respond to standard treatments. The goal is to find the right dose and check if the dru…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Ipsen • Aim: Disease control

Last updated Apr 30, 2026 15:48 UTC

New drug ALE.P02 targets tough cancers in early trial

This study tests a new drug, ALE.P02, designed to find and attack cancer cells that have a specific protein called Claudin-1. It is for adults with advanced or spreading squamous cell cancers of the lung, head and neck, cervix, or esophagus who have already tried standard treatme…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control

Last updated Apr 29, 2026 15:05 UTC

Engineered immune cells take on Hard-to-Treat cancers in early trial

This early-phase study tests a new treatment for people with advanced melanoma or other solid tumors that have spread. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goals are to find a safe dos…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Anusha Kalbasi • Aim: Disease control

Last updated Apr 29, 2026 15:04 UTC

New drug combo shows promise for tough head and neck cancers

This study tests a combination of two experimental drugs, SYS6010 and Enlonstobart, in people with head and neck cancer that has come back or spread. The goal is to see if the treatment can shrink tumors and control the disease. About 70 adults aged 18-75 who have not had prior s…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control

Last updated Apr 29, 2026 15:04 UTC

New cocktail of cancer drugs could shrink head and neck tumors

This study tests whether combining three different medicines can shrink tumors in adults with head and neck cancer that has spread or come back. Participants are split into three groups, each receiving a different mix of the drugs as infusions. The goal is to see if the combinati…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control

Last updated Apr 28, 2026 13:02 UTC

New targeted therapy TER-2013 enters trials for Hard-to-Treat cancers

This study tests an experimental drug called TER-2013 in people with advanced solid tumors (like breast, endometrial, ovarian, lung, head and neck, esophageal, or cervical cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The trial has two phases: first, fi…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control

Last updated Apr 28, 2026 13:02 UTC

New combo therapy aims to improve survival in head and neck cancer

This study tests whether adding petosemtamab to the standard immunotherapy pembrolizumab helps people with advanced head and neck cancer live longer. About 700 adults whose cancer has spread or returned and whose tumors have a specific marker (PD-L1) will be randomly assigned to …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE3 • Sponsor: Merus B.V. • Aim: Disease control

Last updated Apr 28, 2026 13:02 UTC

New scan could reveal hidden cancer spread in head and neck patients

Diagnosis Recruiting now

This early-phase study tests whether a special imaging agent called 89Zr panitumumab can better detect cancer that has spread in people with head and neck cancer. About 60 participants will receive the agent and then have a PET/CT scan. The goal is to see if this new method is mo…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Eben Rosenthal • Aim: Diagnosis

Last updated May 01, 2026 15:26 UTC

Glow-in-the-Dark dye helps surgeons spot hidden cancer cells

Diagnosis Recruiting now

This early-phase trial tests whether combining two imaging techniques—a radioactive scan before surgery and a fluorescent dye during surgery—can help surgeons find and remove head and neck cancer more completely. About 40 adults with head and neck cancer will receive both imaging…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis

Last updated Apr 30, 2026 15:51 UTC

Fat flap may ease neck pain after cancer treatment

This study tests whether a buried fat flap procedure is safe and helpful for reducing neck problems like pain, stiffness, and trouble swallowing after head and neck cancer treatment. About 12 adults who have had radiation and a neck dissection will receive the flap. Researchers w…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief

Last updated May 01, 2026 15:28 UTC

New hope for cancer patients: drug may prevent weight loss during treatment

This study tests whether adding olanzapine to standard nausea care helps head and neck cancer patients maintain their appetite and weight during chemoradiation. About 66 adults will be randomly assigned to receive either olanzapine plus standard care or standard care alone. The m…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief

Last updated May 01, 2026 15:26 UTC

Shorter radiation blasts may bring faster relief for head and neck cancer patients

This study tests whether a shorter course of high-dose radiation (SBRT) can safely reduce symptoms in people with head and neck cancer that cannot be cured. About 108 adults whose cancer has returned or spread will receive either standard or shorter radiation. The goal is to see …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief

Last updated Apr 30, 2026 15:48 UTC

New study tests safer pain relief for cancer patients

This study tests whether a high dose of gabapentin, a non-opioid pain medicine, can prevent the need for opioid painkillers in people with head and neck cancer who get chemotherapy and radiation. Mouth sores from treatment can be very painful, and opioids have serious side effect…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief

Last updated Apr 29, 2026 15:01 UTC

Can a constipation drug help head and neck cancer patients before surgery?

This pilot study is testing whether methylnaltrexone, a drug used for constipation, can be safely given to people with oral cavity squamous cell carcinoma for two weeks before their surgery. The main goal is to check for side effects. About 25 adults whose cancer can be removed b…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE4 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief

Last updated Apr 28, 2026 13:01 UTC

Tiny tumor clones could guide cancer treatment choices

This study looks at whether growing a patient's cancer cells in the lab (called organoids) can accurately predict which drug will shrink their tumor. Researchers will compare the lab test results with how the patient actually responds to treatment. The goal is to see if this appr…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Sponsor: Huashan Hospital • Aim: Knowledge-focused

Last updated May 01, 2026 15:29 UTC

New imaging tracer lights up tumors in first human test

This study tests a new imaging agent that uses special antibodies to highlight tumors on PET/CT scans. About 32 adults with various solid cancers will receive a single injection of the agent to see where it goes in the body and how safe it is. The goal is to learn if this method …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: EARLY_PHASE1 • Sponsor: Var2 Pharmaceuticals • Aim: Knowledge-focused

Last updated May 01, 2026 15:24 UTC

New scan method reveals hidden radiation damage to neck arteries

This study aims to see if a special PET/CT scan using sodium fluoride can better detect radiation damage to neck blood vessels than the standard scan in 20 adults with head and neck cancers. Participants will get both types of scans before and after radiation therapy. The goal is…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: EARLY_PHASE1 • Sponsor: Emory University • Aim: Knowledge-focused

Last updated May 01, 2026 15:24 UTC

Remote hearing checks could save cancer Patients' ears

This study looks at whether offering hearing tests close to home or online can help more head and neck cancer patients get their hearing checked during treatment. Chemotherapy (cisplatin) and radiation can cause hearing loss, but many patients skip follow-up tests. The study will…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused

Last updated Apr 30, 2026 15:52 UTC

New program aims to speed up life-saving radiation for head and neck cancer patients